Iterative Health and the Florida Research Institute (FRI) in the US have collaborated to introduce the former’s artificial intelligence (AI)-Recruitment (AIR) technology in the Florida region.

This will help in expediting the recruitment of patients to clinical trials.

Bringing Iterative Health’s AIR technology to the Florida region will aid in standardising endoscopic scoring and provide better access for patients to more accurate therapeutics through clinical trials.

The implementation of this technology will also enable patient recruitment into trials focused on advancing treatments for inflammatory bowel disease (IBD).

Iterative Health and FRI will help to democratise access to new IBD therapies for all patients.

Florida Research Institute principal investigator and medical director Dr Souvik Sarkar said: “We’re thrilled to partner with Iterative Health in order to advance patient care and increase access to clinical trials for patients in Florida.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

“AIR will streamline the clinical trial identification process, increasing patients’ ability to participate in trials, that may ultimately lead to better treatments and care. Both organisations are passionate about reducing healthcare disparities, and together, we look forward to helping democratise GI care.”

FRI, which provides advanced treatments for patients with liver and gastrointestinal diseases, is connected to several pre-vetted, local, eligible potential trial subjects.

Iterative Health Network Expansion vice-president Scott Lish said: “Our ultimate mission at Iterative Health is to use computer vision-based technology to reduce disparities in healthcare, and we’re excited to collaborate with an organisation like FRI that has a shared goal.

“This partnership with Dr Sarkar and his network of gastroenterologists, combined with our existing relationships with leading pharmaceutical manufacturers to support their active clinical trials, will accelerate the development process of novel IBD therapeutics and improve patient access.”